Dalneva 8 mg/10 mg tablete Chorvatsko - chorvatština - HALMED (Agencija za lijekove i medicinske proizvode)

dalneva 8 mg/10 mg tablete

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - perindopril-tert-butilamin amlodipinbesilat - tableta - 8 mg + 10 mg - urbroj: svaka tableta sadrži 8 mg perindopril-tert-butilamina što odgovara 6,68 mg perindoprila i 10 mg amlodipina u obliku amlodipinbesilata

Dalneva 8 mg/5 mg tablete Chorvatsko - chorvatština - HALMED (Agencija za lijekove i medicinske proizvode)

dalneva 8 mg/5 mg tablete

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - perindopril-tert-butilamin amlodipinbesilat - tableta - 8 mg + 5 mg - urbroj: svaka tableta sadrži 8 mg perindopril-tert-butilamina što odgovara 6,68 mg perindoprila i 5 mg amlodipina u obliku amlodipinbesilata

Jetrea Evropská unie - chorvatština - EMA (European Medicines Agency)

jetrea

inceptua ab - ocriplasmin - bolesti retinoze - ophthalmologicals - jetrea je indicirana kod odraslih osoba za liječenje vitreomakularne vuče (vmt), uključujući kada je povezana s makularnim otvorom promjera manji ili jednak 400 mikrona.

Ixiaro Evropská unie - chorvatština - EMA (European Medicines Agency)

ixiaro

valneva austria gmbh - japanski encefalitis virus, inaktivirano (atenuiranih deformacije sa14-14-2 u vero stanicama) - encephalitis, japanese; immunization - cjepiva - ixiaro je indiciran za aktivnu imunizaciju protiv japanskog encefalitisa kod odraslih, adolescenata, djece i dojenčadi starijih od dva mjeseca i starijih. ixiaro moraju biti uzeti u obzir za uporabu u osoba pod rizikom zaraze kroz putovanja ili u toku svoje zanimanje,.

PreHevbri Evropská unie - chorvatština - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - hepatitis b površinski antigen - hepatitis b - cjepiva - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Evropská unie - chorvatština - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Kigabeq Evropská unie - chorvatština - EMA (European Medicines Agency)

kigabeq

orphelia pharma sas - вигабатрин - spasms, infantile; epilepsies, partial - antiepileptici sredstva, - kigabeq drugačije u bebe i djeca od 1 mjeseca do manje od 7 godina za:liječenje u monoterapija инфантильных grčeva (sindrom vesta). liječenje u kombinaciji s drugim antiepileptika lijekova za pacijente sa otporan парциальной epilepsije (žarišna udara), sa ili bez sekundarne generalizacije, tj. tamo gdje su svi ostali odgovarajući ljekoviti pripravak kombinacije bili su potpuni ili nisu bili tolerantni.

PROSPAN akut 65 mg/1 tableta šumeća tableta Bosna a Hercegovina - chorvatština - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

prospan akut 65 mg/1 tableta šumeća tableta

salveo d.o.o. sarajevo - Сухи ekstrakt list bršljena - šumeća tableta - 65 mg/1 tableta - 1 šumeća tableta sadrži 65 mg suhog ekstrakta lista bršljana (57.5:1)

PROSPAN sirup 0.7 g/100 mL sirup Bosna a Hercegovina - chorvatština - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

prospan sirup 0.7 g/100 ml sirup

salveo d.o.o. sarajevo - Сухи ekstrakt list bršljena - sirup - 0.7 g/100 ml - 1 ml oralne otopine sadrži: 7 mg suhog ekstrakta lista bršljana (57.5:1)

PROSPAN sirup 7 mg/1 mL sirup Bosna a Hercegovina - chorvatština - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

prospan sirup 7 mg/1 ml sirup

salveo d.o.o. sarajevo - Сухи ekstrakt list bršljena - sirup - 7 mg/1 ml - 100 ml oralne otopine sadrži: 0,7 g suhog ekstrakta lista bršljana (57.5:1)